Form 8-K Biodel Inc For: Nov 03

Item 2.05 Costs Associated with Exit or Disposal Activities.

On October 28, 2015, Biodel Inc. ("Biodel") committed to a restructuring plan resulting in a reduction in force affecting 10 employees, none of whom are executives. The restructuring plan is primarily designed to reduce infrastructure costs and improve efficiency of research- and quality-related activities as Biodel focuses on later stage clinical development programs.

Employees directly affected by the reduction in force have received notification and will be provided with severance payments and continuation of benefits for a limited term. The positions impacted are across Biodel's research, quality control and assurance and administrative and facilities departments. As a result of the restructuring plan, Biodel estimates that it will incur one-time cash severance payments of approximately $0.3 million.

Biodel forward-looking statements

This current report on form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the workforce reduction plan and the amount and expected timing of costs, expense savings and other charges related to these activities. These forward-looking statements are based on the current intent and expectations of the management of Biodel. These statements are not guarantees of future performance or actions and involve risks and uncertainties that are difficult to predict. Biodel's actual performance in the timing and outcome of actions and events may differ materially from those expressed or implied in the forward-looking statements because such statements are based on assumptions and projections relating to these activities that are inherently uncertain and may also be affected by risks such as: that the costs related to the workforce reduction plan may be higher than estimated; that the savings related to the workforce reduction plan may be lower than expected; and the other risks and uncertainties described in Biodel's SEC reports filed under the Securities Exchange Act of 1934, including its annual report on Form 10-K for the fiscal year ended September 30, 2014. Except as required by law, Biodel undertakes no obligation to update any forward-looking or other statements in this report, whether as a result of new information, future events or otherwise.